Stock Screener App

Frei -

Installieren

21.34

1.70% -0.37

after-market

Handel nachbörslich: 21.33 -0.01 -0.05%

Ultragenyx Pharmaceutical Inc (RARE)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt RARE? Forum Prognose Aktiensplit

Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten

Ultragenyx’s gene therapy meets co-primary endpoint in Phase III trial - Clinical Trials Arena

DEADLINE: Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - ChartMill

RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit ... - Bluefield Daily Telegraph

RARE's DTX301 Meets First Key Goal in Phase III OTC Deficiency Study - TradingView

Ultragenyx reveals positive Phase III results for DTX301 AAV8 gene therapy - The Pharma Letter

Russell Investments Group Ltd. Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

Ultragenyx reports positive Phase 3 data for OTC gene therapy By Investing.com - Investing.com India

Bank of America, Leerink Maintain Buy/Outperform on RARE Ultragenyx March 2026 - Meyka

JP Morgan Lowers Price Target for Ultragenyx Pharmaceutical (RAR - GuruFocus

Ultragenyx reports positive Phase 3 data for OTC gene therapy - Investing.com Australia

ROSEN, A LEADING LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure ... - Bluefield Daily Telegraph

Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $74.00 Price Target at JPMorgan Chase & Co. - MarketBeat

Leerink Partners reiterates Ultragenyx stock rating on trial data - Investing.com Nigeria

Ultragenyx's Gene Therapy Study Shows Ammonia Reduction In Rare Metabolic Disorder - Benzinga

Ultragenyx Pharmaceutical Inc Announces Positive 36-Week Data From Phase 3 Study Of DTX301 AAV8 Gene Therapy For The Treatment Of Ornithine Transcarbamylase Deficiency - marketscreener.com

BofA reiterates Ultragenyx stock rating on positive gene therapy data - Investing.com

Leerink Partners reiterates Ultragenyx stock rating on trial data By Investing.com - Investing.com India

Ultragenyx gene therapy posts Phase III win for urea cycle disorder - FirstWord Pharma

Ultragenyx posts trial win for gene therapy (RARE:NASDAQ) - Seeking Alpha

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming DeadlinesRARE - PR Newswire

Ultragenyx Announces Positive Phase 3 Results for DTX301 - TipRanks

Ultragenyx (RARE) Sees Positive Phase 3 Results for Gene Therapy - GuruFocus

Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency - The Manila Times

Ultragenyx's gene therapy helps control ammonia levels in late-stage study - marketscreener.com

Ultragenyx Announces Positive 36-Week Data from Phase 3 - GlobeNewswire

RARE SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026 - The Malaysian Reserve

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire

ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire

Ultragenyx Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Ultragenyx Pharmaceutical Inc. - GlobeNewswire Inc.

Assessing Ultragenyx Pharmaceutical (RARE) Valuation After Class Action And Failed Setrusumab Phase III Trials - simplywall.st

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

Growth Value: What are the future prospects of Ultragenyx Pharmaceutical IncTake Profit & Reliable Entry Point Trade Alerts - baoquankhu1.vn

LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION - Finviz

LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (2026-03-11) - Seeking Alpha

Sands Capital Management LLC Cuts Stock Position in Ultragenyx Pharmaceutical Inc. $RARE - MarketBeat

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionRARE - ACCESS Newswire

Insider Sell: Karah Parschauer Sells Shares of Ultragenyx Pharma - GuruFocus

Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 - GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE - ChartMill

RARE Investors Have Opportunity to Lead Ultragenyx - GlobeNewswire

Investors who lost money on Ultragenyx Pharmaceutical Inc.(RARE) should contact The Gross Law Firm about pending Class ActionRARE - PR Newswire

Ultragenyx EVP Pinion sells $228k in shares - Investing.com Nigeria

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Biopharma Brass Hid Drug Trial Risks, Derivative Suit Says - Law360

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit - Financial Times

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ultragenyx - GlobeNewswire

Levi & Korsinsky, LLP: Institutional Investor Notice --- Ultragenyx Pharmaceutical Lead Plaintiff Opportunity - GlobeNewswire

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Up 5.6%Still a Buy? - MarketBeat

Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors - GlobeNewswire

FinancialContentUltragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, DeadlineContact Kessler Topaz Meltzer & Check, LLP - FinancialContent

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Richtech Robotics Inc. (RR), Ultragenyx Pharmaceutical Inc. (RARE), and Mereo BioPharma Group plc (MREO) Announced by Holzer & Holzer, LLC - marketscreener.com

CLASS ACTION INVESTOR ALERTS: Bragar Eagel & Squire, P.C. - GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm - mydailyrecord.com

RARE Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages RARE Investors with Losses to Contact the Firm - Sahm

Ultragenyx Pharmaceutical Inc. (RARE) Investors: April 6, 2026, Filing Deadline in Securities Fraud Class Action - GlobeNewswire Inc.

Ultragenyx Pharmaceutical Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class ActionRGRD Law - marketscreener.com

Analysis Recap: Can Ultragenyx Pharmaceutical Inc. (UP0) stock stage a strong rebound this quarter2025 Trade Ideas & Community Verified Trade Alerts - Naître et grandir

Ultragenyx Pharmaceutical Inc. $RARE Stock Position Increased by Blue Owl Capital Holdings LP - MarketBeat

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to ... - Caledonian Record

ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.

Contact The Gross Law Firm by April 6, 2026 Deadline to Join Class Action Against Ultragenyx ... - Bluefield Daily Telegraph

RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire

Ultragenyx Pharmaceutical Inc. (RARE) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit - FinancialContent

RARE CLASS ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Ultragenyx Investors of Securities Class Action Deadline on April 6, 2026 – Company Announcement - Financial Times

RPRX

$45.65

0.48%

ROIV

$28.06

1.72%

MRNA

$52.56

1.55%

BNTX

$91.19

1.21%

INSM

$139.50

0.01%

ONC

$284.05

0.44%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters